

# Prediction and identification of human leukocyte antigen-A2-restricted cytotoxic T lymphocyte epitope peptides from the human papillomavirus 58 E7 protein

HE WANG, LILAI CHEN, WEIHONG MA, YUE ZENG, LU QIN, MENGJIE CHEN and LI LI

Gynecologist Tumor Department, Affiliated Tumor Hospital of Guangxi Medical University,  
Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China

Received August 15, 2017; Accepted May 3, 2018

DOI: 10.3892/ol.2018.8875

**Abstract.** Persistent infection with high-risk human papilloma virus (HPV) is the primary cause of cervical intraepithelial neoplasia (CIN) and cervical carcinoma. HPV58 is the third most common HPV genotype in China after HPV16 and HPV18. HPV E6 and E7 are oncoproteins and are constitutively expressed in HPV-associated cancer cells, therefore they are considered to be ideal target antigens for immunotherapy, including HPV therapeutic vaccine. In the present study, human leukocyte antigen (HLA)-A2-restricted cytotoxic T lymphocyte (CTL) epitope peptides were predicted and screened from HPV58 E7 antigen and their immunogenicity was subsequently determined. A total of 6 HLA-A2-binding peptides derived from HPV58 E7 were predicted and selected using 3 different prediction programs. A negative control peptide and PBS were used as two negative controls. Peripheral blood mononuclear cells (PBMCs) with HLA-A2(+) allele were used to detect the specific cellular immune response among the 6 predicted peptides by enzyme-linked immunospot assay (ELISOT). Following preliminary screening for the predicted peptides, the antigenicity of the peptide HPV58 E7<sub>72-80</sub> was further assessed by an immunoassay to a vaccine contained HPV58 E7 antigen. Specific humoral and cellular immunity were detected using the peptide HPV58 E7<sub>72-80</sub> as the specific antigen. A total of 6 peptides from HPV58 E7 protein were predicted and subsequently named P1 (E7<sub>7-15</sub>: TLREYILDL), P2 (E7<sub>14-22</sub>: DLHPEPTDL), P3 (E7<sub>69-77</sub>: CINSTTDDV), and P4 (E7<sub>72-80</sub>: STTTDVRTL), P5 (E7<sub>79-87</sub>: TLQQLLMGT) and P6 (E7<sub>83-91</sub>: LLMGTCTIV). In the ELISPOT assay on HLA-A2 (+) human PBMCs, interferon (IFN)- $\gamma$ -production was evident in the P2 and P4 groups. The average numbers of IFN- $\gamma$  associated spots in the P2 and P4

groups was  $50.61 \pm 5.37$  spot-forming cells (SFC)/ $1 \times 10^5$  and  $266 \pm 34.42$  SFC/ $1 \times 10^5$ , respectively. The numbers of spots in the two peptides were significantly increased compared with the other 4 peptides and the control groups ( $P < 0.05$ ). In the further antigenicity verification of P4 (HPV58 E7<sub>72-80</sub>), the peptide only stimulated the humoral immune response of the AD-HPV16/18/58 mE6E7 vaccine containing HPV58 E7 antigen. Compared with the 2 negative control groups (1:400), the antibody titers of the vaccine group (1:25,600) were significantly increased ( $P < 0.05$ ). In cellular immunoassays the average number of IFN- $\gamma$  associated spots was  $143.3 \pm 32.13$  SFC/ $1 \times 10^5$  in the vaccine group, which was significantly enhanced compared with the PBS group ( $8 \pm 5.29$  SFC/ $1 \times 10^5$ ;  $P < 0.01$ ) and the AD-NC group ( $28 \pm 5.13$  SFC/ $1 \times 10^5$ ;  $P < 0.01$ ). The peptide HPV58 E7<sub>72-80</sub> (STTTDVRTL) displayed sufficient antigenicity to a vaccine contained HPV58 E7 antigen. Therefore, HPV58 E7<sub>72-80</sub> peptide may be considered as a candidate epitope peptide for the construction of HPV58 peptide vaccines.

## Introduction

Cervical cancer is the second most common female malignant tumor following breast cancer. High risk human papilloma virus (HPV) has been confirmed as a dominant factor responsible for several anogenital diseases, particularly cervical intraepithelial neoplasia (CIN) and cervical carcinoma (1). Of the more than two hundred HPV genotypes, 16, 18, 31, 45, 52 and 58 are six particularly important, as they are highly correlated with more than 90% of cervical carcinoma cases (2-4). Persistent infection with high risk HPV is the primary factor responsible for cervical cancer (3,4). Although strains 16 and 18 are the two most common high-risk HPV genotypes worldwide, genotype distribution studies in Chinese women have shown that HPV58 is the third most common genotype found in Chinese cervical carcinoma patients after HPV16 and -18 (5). Because HPV58 infection is not common in western countries, current domestic and foreign research on HPV58 is lacking. However, the high rate of HPV58 infection in China firmly indicates that studies investigating HPV58 therapeutic vaccines are necessary.

HPV E7 is an early oncoproteins in HPV and continuously present in cervical cancer cells. These proteins are responsible

---

*Correspondence to:* Professor Li Li, Gynecologist Tumor Department, Affiliated Tumor Hospital of Guangxi Medical University, 71 Hedi Road, ZhongShan Street, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China  
E-mail: lili\_temp@hotmail.com

**Key words:** human papillomavirus, E7 epitope peptide, enzyme linked immunosorbent assay, enzyme-linked immunospot

for the carcinogenicity of HPV (1,6,7). Many studies have showed that sustained expression of oncoproteins E7 is necessary for the tumorigenicity and development of cervical cancer cells (8,9). Accordingly, HPV E7 could be applied as target antigens for a candidate HPV therapeutic vaccine due to their constitutive expression and the maintenance of cellular transformation in HPV-infected cells (3). Because of continuous E7 expression, it is impossible that cervical carcinoma cells can invoke immunologic escape through antigen loss (3). To date, E7 have been extensively confirmed as ideal target antigens for the development of HPV therapeutic vaccines against HPV-related CIN and cervical carcinoma (10).

HPV therapeutic vaccines designed using specific epitope peptides as target antigens can induce specific cellular immune responses, avoid the immunosuppression induced by natural proteins and enhance immune specificity and immune effects. At present, this type of vaccine has become the focus of research in the immunization field. Recently, researchers have found that the cytotoxic T lymphocyte (CTL) epitope of the HPV16 E6 and E7 oncoproteins match human leukocyte antigen (HLA)-A2, which is currently considered the most common human major histocompatibility complex (MHC)-I molecule; the immunogenicity of these epitope has been confirmed using transgenic mice (11). *In vitro*, lymphocytes from human peripheral blood previously immunized with the HPV16 polypeptide vaccine induced specific CTL immune responses and killed HPV16-positive tumor cells (12,13). However, the CTL epitope for HPV58 has not been found. In view of the high HPV58 infection rate in China, we attempted to find specific CTL epitope antigens in the HPV58 E7 proteins and to prepare corresponding polypeptide vaccines to treat cervical cancer.

To achieve our goal, we screened HLA-A2-restricted HPV58 E7 CTL epitope peptides and evaluated their immune responses. The resulting epitope peptides may serve as candidate epitope for the preparation of an HPV58 therapeutic epitope peptide vaccine.

## Materials and methods

**Peptide prediction and synthesis.** The full-length amino acid sequences of the HPV58 E7 (accession no. AEJ33545.1) proteins were obtained from GenBank. The HPV58 E7 protein is composed of 98 amino acids, and its sequence is as follows: MRGNPTLREYILDHLPEPTDLFCYEQLCDSSDEDEIGLDRPDGQAQPATANYIYVTCCTTCGTTVRLCINSTT DVRTLQQLMGCTCTIVCPSCAQQ.

The predicted peptides used for the identification of CTL epitopes were selected on the basis of 3 different prediction programs from internet websites that include an HLA binding peptide prediction ([http://www.bimas.cit.nih.gov/molbio/hla\\_bind/](http://www.bimas.cit.nih.gov/molbio/hla_bind/)).

SYFPEITHI (<http://www.syfpeithi.de/Scripts/MHCServer.dll/EpitopePrediction.htm>), and an MHC class I-binding prediction using an artificial neural network ([http://tools.immuneepitope.org/analyze/html\\_mhci\\_binding\\_20090901/mhc\\_binding.html](http://tools.immuneepitope.org/analyze/html_mhci_binding_20090901/mhc_binding.html)).

The predicted peptides each containing nine amino acid were synthesized by solid phase peptide synthesis and purified by reversed-phase high performance liquid chromatography by Abgent (San Diego, CA, USA). The negative control peptide

(irrelevant peptide) from the SARS coronavirus (CoV) spike protein (LYLTQDLFL) was synthesized and purified in the same way by GL Biochem Co., Ltd. (Shanghai, China). The mass of each peptide was 30 mg and the purity of exceeded 93%.

**Isolation and culture of peripheral blood mononuclear cells (PBMC).** A total of 100 ml peripheral blood from HLA-A2 (+) healthy women volunteers was drawn with a vacuum bag from the basilic vein. Our study using volunteers' samples was approved by the ethical committee of Guangxi Medical University Affiliated Tumor Hospital. Written informed consent was obtained from all volunteers. Human PBMC were separated from the peripheral blood using Ficoll density gradient separation method. The final concentration of PBMC was  $1 \times 10^5$ , diluted with RPMI-1640 containing 10% FBS. The final volume added to the well was 100  $\mu$ l. These cells were inoculated at 24-well culture plate and stimulated with 10  $\mu$ g/ml of the six predicted peptides or negative control peptide, respectively. At the same time, the cells were added 100 U/ml interleukin 2 every other day. Three times of stimulation by the peptides and IL-2, the PBMC were collected for ELISPOT.

**ELISPOT Assay on human PBMC.** The human PBMC, which were HLA-A2 (+) and activated by the 6 predicted peptides or negative control peptide, were detected special immune spots by an ELISPOT kit (DKW22-1000-096S; Dakewe Biotech Co., Ltd., Shenzhen, China). Briefly, a 96-well nitrocellulose plate precoated with anti-human interferon (IFN)- $\gamma$  antibody was placed at 4°C overnight and then blocked the following day with RPMI-1640 medium containing 10% FBS. PBMC were added to the wells at a concentration of  $1 \times 10^5$  cells/well in a volume of 100  $\mu$ l. These cells were stimulated with 10  $\mu$ g/ml of the six predicted peptides, negative control peptide, phorbol-12-myristate-13-acetate (PHA) (5 ng/ml; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and PBS, respectively. PHA served as the positive control, and the negative control peptide and PBS served as the negative controls. The plate was incubated at 37°C in 5% carbon dioxide for 24 h. The next day, the plate was incubated with a biotinylated anti-human IFN- $\gamma$  antibody (primary antibody) for 2 h at room temperature. Unbound primary antibody was removed by washing with scrubbing solution, and a streptavidin-HRP antibody (secondary antibody) was added. Following 1 h of incubation at room temperature, the unbound secondary antibody was removed by washing with scrubbing solution, and staining with AEC (3-amino-9-ethylcarbazole) substrate solution was carried out for 20 min. The plate was washed and air dried for 24 h. The immune spots, which represented individual IFN- $\gamma$ -producing cells as spot-forming cells (SFC) on the membrane, were enumerated by the KS-ELISPOT automatic system (Dakewe Biotech Co., Ltd.). The responses were considered positive when the IFN- $\gamma$  associated spot numbers produced by predicted peptides stimulation were above 50 SFC/well compared with the responses obtained with all the negative control peptide, P-values  $\leq 0.05$  were considered significant.

**Antigenicity verification of HPV58 E7<sub>72-80</sub> peptide.** Before further immune evaluation to the peptide HPV58 E7<sub>72-80</sub> (STTTDVRTL), a mice cervical cancer cell line U14/LV-HPV58E6E7 and an

adenovirus vector vaccine AD-HPV16/18/58 mE6E7 containing HPV58 E7 antigen were constructed by the authors. Our animal experiments were approved by the ethical committee of GuangXi medical university affiliated tumor hospital. Thirty female C57BL/6 mice, 6-8 weeks old, weighed approximately 20 to 25 g, were randomly divided into three groups as follows: PBS group, AD-NC (empty adenovirus vector) group, and AD-HPV16/18/58 mE6E7 vaccine group. It is  $n=10$  in each group. C57BL/6 mice were subcutaneously injected on the back of the mice with  $1 \times 10^6/100$   $\mu$ l the mice cervical cancer U14/LV-HPV58E6E7 cells which can express HPV58 E6E7 fusion protein. The PBS, AD-NC or AD-HPV16/18/58 mE6E7 vaccine was individually administered by tattooing on day 7, 14, and 21 after the cancer cells challenge. Two weeks after the last immunization, serum and splenocytes were isolated individually from blood and spleen of the immunized mice. The peptide HPV58 E7<sub>72-80</sub> was used as antigen to activate the immunized mice serum and splenocytes before ELISA and ELISPOT assay. HPV58 related serum specific antibody was detected by enzyme-linked immunosorbent assay (ELISA) using an ELISA kit following the manufacturer's instructions (DKW-F1; Dakewe Biotech Co., Ltd.). IFN- $\gamma$ -spots of the splenocytes were detected using an ELISPOT kit (DKW22-2000-096S; Dakewe Biotech Co., Ltd.). Briefly, a 96-well nitrocellulose plate precoated with anti-mice IFN- $\gamma$  antibody was placed at 4°C overnight and then blocked the following day with RPMI-1640 medium containing 10% FBS. Immunized mice splenocytes were added to the wells at a concentration of  $1 \times 10^5$  cells/well in a volume of 100  $\mu$ l. These cells were stimulated with 10  $\mu$ g/ml of the peptide HPV58 E7<sub>72-80</sub>. The plate was incubated at 37°C in 5% carbon dioxide for 24 h. The next day, the plate was incubated with a biotinylated anti-mice IFN- $\gamma$  antibody (primary antibody) for 2 h at room temperature. Unbound primary antibody was removed by washing with scrubbing solution, and a streptavidin-HRP antibody (secondary antibody) was added. Following 1 h of incubation at room temperature, the unbound secondary antibody was removed by washing with scrubbing solution, and staining with AEC (3-amino-9-ethylcarbazole) substrate solution was carried out for 20 min. The plate was washed and air dried for 24 h. The immune spots, which represented individual IFN- $\gamma$ -producing cells as SFC on the membrane, were enumerated by the KS-ELISPOT automatic system (Dakewe Biotech Co., Ltd.). The production of IFN- $\gamma$  associated spots indicated that the peptide HPV58 E7<sub>72-80</sub> can activate the mice splenocytes which were immunized by the AD-HPV16/18/58 mE6E7 vaccine containing HPV58E7 gene. The responses were considered positive when the spot numbers produced in AD-HPV16/18/58 mE6E7 vaccine group were above 50 SFC/well compared with the responses obtained with PBS group and AD-NC group,  $P$ -values  $\leq 0.05$  were considered significant.

**Statistical analysis.** The SPSS 22.0 software (IBM Corp., Armonk, NY, USA) was used for all statistical analyses. IFN-ELISPOT assay and ELISA were evaluated using an analysis of variance (ANOVA). Results are expressed as means  $\pm$  standard deviation (SD). To identify significant differences between groups, Student's  $t$ -test was used. For all comparisons,  $P < 0.05$  was considered to indicate a statistically significant difference. All findings were confirmed in at least one additional independent experiment.

## Results

**Peptide prediction and analysis results.** Several peptide prediction programs were used to assist in the identification of candidate CTL epitope. According to the prediction results of the three programs, the top-ranked six peptides in HPV58 E7 were selected are shown in Table I.

**Evaluation of HPV58 E7 peptide-specific T cell immunity in HLA-A2 (+) human PBMC.** IFN- $\gamma$  ELISPOT assay was performed on the HLA-A2 (+) human PBMC using a final concentration of 10  $\mu$ g/ml of the 6 candidate peptides of HPV58 E7. IFN- $\gamma$ -positive spots were detected in the PHA (the positive control), P2 and P4 groups, whereas other experimental groups and the two negative control groups (negative control peptide group and PBS group) exhibited no or few spots formation (Fig. 1). The average numbers of IFN- $\gamma$ -positive spots in the PHA, the negative control peptide, PBS, P1, P2, P3, P4, P5 and P6 groups were  $737 \pm 17.54$  SFC/ $1 \times 10^5$ , 0, 0, 0,  $50.61 \pm 5.37$  SFC/ $1 \times 10^5$ ,  $5.62 \pm 4.78$  SFC/ $1 \times 10^5$ ,  $266 \pm 34.42$  SFC/ $1 \times 10^5$ ,  $13.33 \pm 1.53$  SFC/ $1 \times 10^5$ ,  $21.61 \pm 5.37$  SFC/ $1 \times 10^5$ , respectively. The average numbers of IFN- $\gamma$ -positive spots in the PHA, P2 and P4 groups were significantly higher than other experiment groups and the two negative control groups ( $P < 0.05$ ; Fig. 1).

### Antigenicity verification of the peptide HPV58 E7<sub>72-80</sub>

**The humoral immunogenicity of the peptide HPV58 E7<sub>72-80</sub>.** On day 14 after the last immunization, blood was collected from the orbital veins of the mice, and sera were isolated. The peptide HPV58 E7<sub>72-80</sub> was added to 96-well plate as stimulation antigen. Then the serum of mice immunized with PBS, AD-NC, and AD-HPV16/18/58 mE6E7 vaccine was added to 96-well plate. Specific humoral immune response associated with HPV58E7 was detected by ELISA. After ELISA was completed, the absorbance of each hole of 96 holes was detected. Absorbance value more than 0.1 can be judged as positive. The maximum dilution of the positive results was regarded as the antibody titer of the predicted peptides. As shown in Fig. 2, on the 14th day of the last immunization, with the prediction peptide HPV58 E7<sub>72-80</sub> as antigen, the AD-HPV16/18/58 mE6E7 vaccine containing HPV58 E7 protein can produce specific antibody in the immunized mice serum. The antibody titers of vaccine group were 1:25,600, but the antibody titers of PBS group and AD-NC group were 1:400. Compared with the two control groups, the antibody titers of AD-HPV16/18/58 mE6E7 vaccine were significantly increased ( $P < 0.05$ ). HPV58 E7<sub>72-80</sub> peptide can activate humoral immunogenicity of the mice immunized by the vaccine containing HPV58E7 antigen.

**Cellular immunogenicity of the peptide HPV58 E7<sub>72-80</sub>.** To test cellular immunogenicity of the peptide HPV58 E7<sub>72-80</sub>, PBMC from the immunized mice were isolated and added to a 24-well plate at a concentration of  $2 \times 10^5$  cells/well and in a volume of 200  $\mu$ l. Then the cells were stimulated with 10  $\mu$ g/ml of the peptide HPV58 E7<sub>72-80</sub>. IL-2 100 u/ml was added to the cells every other day. The splenocytes were co-cultured with the peptide HPV58 E7<sub>72-80</sub> for a week. Seven days later, the splenocytes from the immunized mice were tested directly ex vivo in IFN- $\gamma$  Elispot assays against the peptide HPV58 E7<sub>72-80</sub>. AD-HPV16/18/58 mE6E7 vaccine can induce specific cellular



Table I. Prediction results for HPV58 E7 epitope peptides.

Peptide number	The initial position of the amino acid	The terminal position of the amino acid	Amino acid sequence
P1	7	15	TLREYILDL
P2	14	22	DLHPEPTDL
P3	69	77	CINSTITDV
P4	72	80	STTTDVRTL
P5	79	87	TLQQLMGT
P6	83	91	LLMGTCTIV

HPV, human papilloma virus.




Figure 1. HPV58 E7-specific T-cell response to the candidate peptides in human leukocyte antigen-A2 (+) human PBMC as measured by IFN- $\gamma$  enzyme-linked immunospot assay. IFN- $\gamma$ -positive spots were detected in the PHA, P2 and P4 groups, whereas other experimental groups and the two negative control groups exhibited no or few spots formation. The average numbers of IFN- $\gamma$ -positive spots in the PHA, P2 and P4 groups were  $737 \pm 17.54$  SFC/ $1 \times 10^5$ ,  $50.61 \pm 5.37$  SFC/ $1 \times 10^5$ ,  $266 \pm 34.42$  SFC/ $1 \times 10^5$ , respectively. The spot numbers in these three groups were significantly higher than other experiment groups and the two negative control groups. \* $P < 0.05$  vs. the PBS group. # $P < 0.05$  vs. the irrelevant peptide group. IFN, interferon; PBS, phosphate-buffered saline; SFC, spot-forming cells; HPV58 E7, human papillomavirus; PBMC, peripheral blood mononuclear cells; PHA, positive control.

immune responses against the HPV58 E7<sub>72-80</sub> peptide in the C57BL/6 mice after three immunizations, the average number of IFN- $\gamma$ -positive spots was  $143 \pm 32.13$  SFC/ $1 \times 10^5$ . The positive spots were significantly increased compared with the negative groups as PBS ( $8 \pm 5.29$  SFC/ $1 \times 10^5$ ,  $P < 0.01$ ) and AD-NC empty vector ( $8 \pm 5.13$  SFC/ $1 \times 10^5$ ,  $P < 0.01$ ) (Fig. 3). HPV58 E7<sub>72-80</sub> peptide can also activate cellular immunogenicity of the mice immunized by the vaccine containing HPV58 E7 antigen.

## Discussion

Peptide vaccines have attracted increasing attention because they possess the ability to induce a single specific immune response. At present, studies evaluating HPV therapeutic polypeptide vaccines have focused on the HPV E6 and E7 proteins and their CTL epitope (14). The HPV E6 and E7 proteins




Figure 2. The 14th day antibody titers in three groups following the final immunization. The antibody titers of AD-HPV16/18/58 mE6E7 vaccine group were 1:25,600. The antibody titers of the PBS and AD-NC group were 1:400. Compared with the two control groups, the antibody titers of the AD-HPV16/18/58 mE6E7 vaccine group were significantly increased \* $P < 0.05$  vs. the PBS group and # $P < 0.05$  vs. the AD-NC group. PBS, phosphate-buffered saline; HPV, human papillomavirus.

contain multiple CTL epitope that have high affinity for HLA class I molecules. Therefore, we can identify epitope peptides with both strong immunogenicity and high specificity (15). This process is key for the preparation of HPV therapeutic polypeptide vaccines. Despite the high HPV58 infection rate in south China, where HPV58 is third after HPV16 and 18, the HPV58 infection rate is very low in western countries; moreover, HPV58 infection distribution differs by region. Research and development of HPV58 peptide vaccines has not received much attention because no accepted CTL epitope has been identified to date. Thus, the study and development of related therapeutic vaccines are difficult.

Specific cellular immunity mediated by CTL plays a key role in cancer immunity. Effector T cells mainly recognize CTL epitopes that are bound to MHC-I molecules to induce cytotoxic cytotoxicity (16). HLA-I molecules are key to antigen presentation and activation of T cells. It is very important for the antigen presentation of virus antigen, tumor antigen, and so on. HLA-A2 is the most specific HLA-I molecule. Its distribution has significant ethnic, ethnic and geographical differences. Studies have shown that the frequency of allele distribution varies from 10 to 40% in different ethnic groups. HLA-A2 (+) accounts for approximately 53% of Chinese population (17).




Figure 3. Specific T-cell responses were tested directly *ex vivo* in IFN- $\gamma$  enzyme-linked immunospot assay against the HPV58 E7<sub>72-80</sub> peptide. The average number of IFN- $\gamma$ -positive spots was  $143.3 \pm 32.13$  SFC/ $1 \times 10^5$  in the AD-HPV16/18/58 mE6E7 vaccine group. The positive spots were significantly enhanced compared with those of control mice immunized with PBS group ( $8 \pm 5.29$  SFC/ $1 \times 10^5$ ), or AD-NC empty vector group ( $28 \pm 5.13$  SFC/ $1 \times 10^5$ ). \* $P < 0.01$  vs. the PBS group and # $P < 0.01$  vs. the AD-NC group. IFN, interferon; PBS, phosphate-buffered saline; SFC, spot-forming cells; HPV58 E7, human papillomavirus; AD, adenovirus; NC, negative control.

Therefore, it is important to study the HPV58 E6 and E7 HLA-A2-restricted CTL epitope peptide in Chinese population. At present, some HLA-A2 (+) CTL epitopes in HPV16 E7 protein, such as E7<sub>11-19</sub> and E7<sub>49-57</sub>, have been identified and accepted (18-20). At present, many studies have confirmed the effectiveness of these epitopes as antigen targets (21-24). However, there are few studies about HPV58. Chan identified three HLA-A11-restricted HPV58 E7 peptides (amino acid positions 78 to 86, 74 to 82, and 88 to 96) showed a positive response, but without HLA-A2-restricted E7 peptides (25). Sabah confirmed the peptide region for the E7 protein ranged from 27 to 33 amino acids and a 9-m epitopes, SSDEDEIGL, in HPV58 E7 were the most potential T cell epitope. And the peptide sequences could interact with as many as seven MHC-I alleles and showed population coverage up to 90.31% (26).

The CTL epitope for the HPV E6 and E7 antigens were screened by acid elution or the use of synthetic overlapping peptides. However, these two methods are costly and time consuming; additionally, the methods can result in a high miss rate because four to eight amino acid residues are separated by two overlapping peptide segments. Time and money can be saved by using internationally recognized epitope prediction sites. Therefore, in our study, HPV58 E7 HLA-A2-restricted CTL epitope peptides were predicted using several related websites: the HLA binding peptide prediction website HLA Peptide Binding Predictions, [http://www.bimas.cit.nih.gov/molbio/hla\\_bind/](http://www.bimas.cit.nih.gov/molbio/hla_bind/); SYFPEITH, <http://www.syfpeithi.de/>; and epitope prediction and analysis tools, <http://tools.immune-epitope.org/main/> (27). After a comprehensive analysis, we preliminarily identified 6 CTL antigen peptides in HPV58

E7 that were subsequently named P1 (E7<sub>7-15</sub>: TLREYILDL), P2 (E7<sub>14-22</sub>: DLHPEPTDL), P3 (E7<sub>69-77</sub>: CINSTTDDV), and P4 (E7<sub>72-80</sub>: STTTDVRTL), P5 (E7<sub>79-87</sub>: TLQQLLMGT), P6 (E7<sub>83-91</sub>: LLMGTCTIV).

In the next study, HLA-A2 (+) PBMC were collected and co-cultured with the six predicted peptides, respectively. In the evaluation of HPV58 E7 peptide-specific T cell immunity in HLA-A2 (+) human PBMC, IFN- $\gamma$ -production was evident by ELISPOT assay in the P2 and P4 groups. The average numbers of IFN- $\gamma$ -positive spots in groups P2 and P4 were significantly increased compared to other four experiment groups and the two negative control groups. And P4 showed the strongest response. Therefore, we chose P4 (E7<sub>72-80</sub>: STTTDVRTL) to continue our study. To be viewed as good peptide epitope, a particular sequence must have some key properties. Firstly, the epitope has to be fairly well conserved among HPV's proteome. Secondly, the epitope has capacity that ensures processivity. In addition, the processed peptide has to be able to interact with MHC alleles, and finally the interacting MHC allele should have good population coverage. E7<sub>72-80</sub> was chosen from HPV58 E7 conserved sequence and fulfilled all the parameters mentioned here.

In the further antigenicity verification of the peptide HPV58 E7<sub>72-80</sub>, this peptide can activate not only humoral but also cellular immune reaction of AD-HPV16/18/58 mE6E7 vaccine containing HPV58 E7 antigen, but not the negative control groups as PBS and AD-NC. The antibody titers of the vaccine group were significantly increased. In cellular immunoassays, the average number of IFN- $\gamma$ -positive spots in the AD-HPV16/18/58 mE6E7 vaccine group was significantly enhanced compared with PBS group and AD-NC group. This result preliminarily confirmed that the peptide HPV58 E7<sub>72-80</sub> can be used as an HLA-A2-restricted CTL epitope peptide. It can be used as a candidate peptide for peptide vaccine development.

Overall, peptide vaccines are considered to be safe, easy to produce and stable (28). However, their low immunogenicity must first be overcome. Another limitation of peptide-based vaccines is the need to match the patient's HLA that makes it difficult to develop a peptide-based vaccine applicable to the whole population. HPV58 E7<sub>72-80</sub> is a HLA-A2-restricted CTL epitope peptide and has good antigenicity. HLA-A2 (+) accounts for more than 50% of Chinese population. Therefore, this result provided a potential target epitope for HPV58 E7 protein and lay the foundation for the construction and identification of HPV58 peptide vaccines.

#### Acknowledgements

The authors would like to thank Dr Zhijun Yang and Dr Qi Wang for their expert advice in molecular biology, cell culture and animal experimentation.

#### Funding

This work was supported by the National Natural Science Foundation of China (grant no. 81260386), the Natural Science Foundation of Guangxi (grant no. 2013GXNSFAA019192), the Patent project of Guangxi colleges and Universities (grant no. KY2015ZL021), and the Research and Development Project of Guangxi Medical and Health Appropriate Technology (grant no. S201511).

## Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

## Authors' contributions

HW performed the experiments and wrote the manuscript. LC predicted and selected the epitopes. WM performed the animals experiment about immunity. YZ divided the lymphocyte from peripheral blood. LQ carried out the immunity test. MC analyzed the experiments data. LL designed and conducted the experiments. All authors read and approved the final manuscript.

## Ethics approval and consent to participate

Not applicable.

## Consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## References

- Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ and Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol* 189: 12-19, 1999.
- Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R and Shah KV: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. *J Natl Cancer Inst* 87: 796-802, 1995.
- Maleki Z: Human papilloma virus vaccination: Review article and an update. *World J Obstet Gynaecol* 5: 16-27, 2016.
- Varughese J and Richman S: Cancer care inequity for women in resource-poor countries. *Rev Obstet Gynecol* 3: 122-132, 2010.
- Lo KW, Wong YF, Chan MK, Li JC, Poon JS, Wang VW, Zhu SN, Zhang TM, He ZG, Wu QL, *et al*: Prevalence of human papillomavirus in cervical cancer: A multicenter study in China. *Int J Cancer* 100: 327-331, 2002.
- Callejas-Valera JL, Iglesias-Bartolome R, Amornphimoltham P, Palacios-Garcia J, Martin D, Califano JA, Molinolo AA and Gutkind JS: mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6/E7 mouse model. *Carcinogenesis* 37: 1014-1025, 2016.
- McLachlin CM: Human papillomavirus in cervical neoplasia. Role, risk factors and implications. *Clin Lab Med* 20: 257-270, 2000.
- Ullman CG and Emery VC: Transforming proteins of human papillomaviruses. *Rev Med Virol* 6: 39-55, 1996.
- Münger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M and Huh K: Mechanisms of human papillomavirus-induced oncogenesis. *J Virol* 78: 11451-11460, 2004.
- Wain G: The human papillomavirus (HPV) vaccine, HPV related diseases and cervical cancer in the post-reproductive years. *Maturitas* 65: 205-209, 2010.
- Bounds CE, Hu J, Cladel NM, Balogh K and Christensen ND: Vaccine generated immunity targets an HPV16 E7 HLA-A2.1-restricted CD8(+) T cell epitope relocated to an early gene or a late gene of the cottontail rabbit papillomavirus (CRPV) genome in HLA-A2.1 transgenic rabbits. *Vaccine* 29: 1194-1200, 2011.
- Chen L, Mizuno MT, Singhal MC, Hu SL, Galloway DA, Hellström I and Hellström KE: Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. *J Immunol* 148: 2617-2621, 1992.
- Nurkkala M, Wassén L, Nordström I, Gustavsson I, Slavica L, Josefsson A and Eriksson K: Conjugation of HPV16 E7 to cholera toxin enhances the HPV-specific T-cell recall responses to pulsed dendritic cells in vitro in women with cervical dysplasia. *Vaccine* 28: 5828-5836, 2010.
- Zheng Y, Zhang Y, Ma Y, Wan J, Shi C and Huang L: Enhancement of immunotherapeutic effects of HPV16E7 on cervical cancer by fusion with CTLA4 extracellular region. *J Microbiol* 46: 728-736, 2008.
- Gan L, Jia R, Zhou L, Guo J and Fan M: Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine. *PLoS One* 9: e108892, 2014.
- Ren F, Xu Y, Mao L, Ou R, Ding Z, Zhang X, Tang J, Li B, Jia Z, Tian Z, *et al*: Heat shock protein 110 improves the antitumor effects of the cytotoxic T lymphocyte epitope E7(49-57) in mice. *Cancer Biol Ther* 9: 134-141, 2010.
- Rötzschke O, Falk K, Stevanović S, Jung G and Rammensee HG: Peptides motif of closely related HLA class I molecules encompass substantial differences. *Eur J Immunol* 22: 2453-2456, 1992.
- Speidel K, Osen W, Faath S, Hilgert I, Obst R, Braspenning J, Momburg F, Hämmerling GJ and Rammensee HG: Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: Conditions, efficiency, and relation to antibody responses. *Eur J Immunol* 27: 2391-2399, 1997.
- Schäfer K, Müller M, Faath S, Henn A, Osen W, Zentgraf H, Benner A, Gissmann L and Jochmus I: Immune response to human papillomaviruses 16 L1E7 chimeric virus-like particles: Induction of cytotoxic T cells and specific tumor protection. *Int J Cancer* 81: 881-888, 1999.
- Xu YS, Hao F, Song ZQ, Zhong B, Hao J and Ye Q: Screening and Identification of Predicted Epitopes of HLA-A2-restricted Cytotoxic T Lymphocytes Derived from the HPV16 E7 Antigen. *Chin J Dermatol* 37: 283-284, 2004 (In Chinese).
- Riemer AB, Keskin DB, Zhang G, Handley M, Anderson KS, Brusic V, Reinhold B and Reinherz EL: A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. *J Biol Chem* 285: 29608-29622, 2010.
- Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karon RA, *et al*: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. *J Natl Cancer Inst* 93: 284-292, 2001.
- Chen S, Ou R, Tang J, Deng X, Wu Y, van Velkinburgh JC, Ni B and Xu Y: Enhanced anti-tumor effects of HPV16E7(49-57)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150. *Cancer Epidemiol* 37: 172-178, 2013.
- Yao Y, Huang W, Yang X, Sun W, Liu X, Cun W and Ma Y: HPV-16 E6 and E7 protein T cell epitopes prediction analysis based on distributions of HLA-A loci across populations: An in silico approach. *Vaccine* 31: 2289-2294, 2013.
- Chan PK, Liu SJ, Cheung TH, Yeo W, Ngai SM, Cheung JL, Chong P and Man S: T-cell response to human papillomavirus type 58 L1, E6, and E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer. *Clin Vaccine Immunol* 17: 1315-1321, 2010.
- Sabah SN, Gazi MA, Sthity RA, Husain AB, Quyyum SA, Rahman M and Islam MR: Designing of epitope-focused vaccine by targeting E6 and E7 conserved protein sequences: An immuno-informatics approach in human papillomavirus 58 isolates. *Interdiscip Sci*: 17 Sep 2016 (Epub ahead of print).
- Tu SH, Huang HI, Lin SI, Liu HY, Sher YP, Chiang SK, Chong P, Roffler S, Tseng GC, Chen HW and Liu SJ: A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo. *J Immunother* 35: 235-244, 2012.
- Rudolf MP, Man S, Melief CJ, Sette A and Kast WM: Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. *Clin Cancer Res* 7 (3 Suppl): 788s-795s, 2001.